Sulfated maltoheptaose

Drug Profile

Sulfated maltoheptaose

Latest Information Update: 07 Feb 2001

Price : $50

At a glance

  • Originator Glycomed
  • Class Antivirals
  • Mechanism of Action Glycosaminoglycan inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Chlamydial infections; Herpes simplex virus infections; HIV infections

Most Recent Events

  • 07 Feb 2001 Discontinued-Preclinical for HIV infections prevention in USA (Vaginal)
  • 07 Feb 2001 Discontinued-Preclinical for Chlamydial infections in USA (Vaginal)
  • 07 Feb 2001 Discontinued-Preclinical for Herpes simplex virus infections in USA (Vaginal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top